Changes in Brain Metabolite Concentrations after Neonatal Hypoxic-ischemic Encephalopathy

Area of Science:

• Neonatal Neurology
• Neuroimaging
• Biochemistry

Background:

• Neonatal hypoxic-ischemic encephalopathy (HIE) is a major cause of brain injury in newborns.
• Early and accurate prediction of HIE outcomes is crucial for timely intervention.
• Proton MR spectroscopy offers a non-invasive method to assess brain metabolites.

Purpose of the Study:

• To examine how brain metabolite concentrations change over time in neonates with HIE.
• To determine the predictive value of these metabolite changes for adverse neurodevelopmental outcomes.

Main Methods:

• Proton MR spectroscopy was used to measure deep gray matter metabolite concentrations in 68 neonates with HIE at two time points: 18-96 hours and 7-14 days post-birth.
• Adverse outcome was defined as death or neurodevelopmental impairment at 18-22 months.
• Receiver operating characteristic (ROC) curves were analyzed to assess predictive accuracy.

Main Results:

• At 18-96 hours, neonates with adverse outcomes showed lower N-acetylaspartate and creatine, and higher lactate and glutamate-glutamine (Glx) levels compared to those with favorable outcomes.
• Metabolite levels decreased from the early to the later time point in neonates with adverse outcomes, but remained stable in those with favorable outcomes.
• Early measurements (18-96 hours) of N-acetylaspartate (AUC 0.98) and lactate (AUC 0.96) were highly predictive of adverse outcomes. Later measurements (7-14 days) showed sustained predictive power for N-acetylaspartate (AUC 0.97) and creatine (AUC 0.97).

Conclusions:

• Time-dependent reductions in N-acetylaspartate and creatine concentrations are reliable predictors of adverse outcomes in HIE.
• While elevated lactate and Glx levels in the acute phase can indicate HIE severity, their predictive value diminishes over time.
• MR spectroscopy-based metabolite profiling offers a powerful tool for prognostication in neonatal HIE.